Emerging treatment therapies targeting conditions earlier in the care continuum have been impacting demand for Nevro’s prized SCS portfolio. The company’s own SI offerings are solutions for ...

On February 7, 2025, Nevro Corp was acquired by Globus ... that was initially anticipated based on clinical trial outcomes. The U.S. SCS market remains highly competitive, with larger companies ...

Nevro’s comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful ...

In addition to the U.S. market release, Nevro introduced the HFX iQ SCS system in select European ... as well as U.S. trial ...

Nevro Corp. NVRO reported ... by ongoing softness in the U.S. SCS market and competitive pressures. Total U.S. permanent implant procedures, as well as U.S. trial procedures, declined in the ...

U.S. permanent implant procedures decreased by 7.0% compared with the fourth quarter of 2023, and U.S. trial ... treatment. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform ...

Total U.S. permanent implant procedures declined 7% year over year, while U.S. trial procedures decreased ... powers the HFX iQ spinal cord stimulation (SCS) system. In addition to the U.S. market ...